Woman in her 70s 'gets life back' after shedding six stone
Pauline Spencer, from Cromer, decided she wanted to lose weight two years ago when she was battling low self-esteem.
She went to see her GP for help and was put on a waiting list for a referral for weight loss injections.
Pauline Spencer initially saw her GP about taking a weight loss injection (Image: Supplied)
The GP suggested she join her local Slimming World group for support while she waited.
Her consultant Steve and the rest of the group were so helpful that the pounds started dropping off in no time, and she no longer felt the need to take the medication.
"I've now found the magic want I thought didn't exist," Pauline said.
READ MORE:
Pauline was fed up of living with obesity and low self esteem (Image: Supplied)
"And it wasn't a drug!"
After the weight loss, Pauline has felt much happier in her own body and mind.
The 71-year-old can join her friends for early morning walks, dance sessions and fitness classes.
READ MORE: NNUH team wins national award for innovative patient monitoring system
Pauline now feels better than ever (Image: Supplied)
She has also started running craft and hobby sessions in the local area, which her former self never would have imagined doing.
Pauline has just nine pounds left to lose until she reaches her target, but consultant Steve said she is "already a winner in every way that matters".
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
3 Penny Stocks With Market Caps Over $70M Worth Watching
Over the last 7 days, the market has remained flat, while in the past 12 months it has risen by 14%, with earnings expected to grow by 15% per annum over the next few years. For investors willing to explore beyond established names, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities. Although "penny stocks" might seem like an outdated term, their potential for growth and affordability remains significant, especially when these companies boast strong financials and balance sheet resilience. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.70 $524.41M ★★★★★★ CuriosityStream (CURI) $4.46 $249.3M ★★★★★★ WM Technology (MAPS) $0.9714 $159.1M ★★★★★★ Perfect (PERF) $2.37 $234.25M ★★★★★★ Tuniu (TOUR) $0.9326 $100.29M ★★★★★★ Safe Bulkers (SB) $4.13 $414.36M ★★★★☆☆ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.83 $6.01M ★★★★★★ Lifetime Brands (LCUT) $4.68 $99.74M ★★★★★☆ North European Oil Royalty Trust (NRT) $4.96 $43.75M ★★★★★★ Click here to see the full list of 417 stocks from our US Penny Stocks screener. Let's review some notable picks from our screened stocks. Zura Bio Simply Wall St Financial Health Rating: ★★★★★★ Overview: Zura Bio Limited is a clinical-stage biotechnology company focused on developing medicines for immune and inflammatory disorders in the United States, with a market cap of $79.82 million. Operations: No revenue segments have been reported. Market Cap: $79.82M Zura Bio, a clinical-stage biotechnology company with a market cap of US$79.82 million, is currently pre-revenue, highlighting its early development stage. The recent appointment of Eric Hyllengren as CFO brings extensive financial leadership experience from the biotech sector, potentially strengthening Zura's strategic finance and operational execution. Despite having no debt and sufficient cash runway for over three years, the company's shares are highly volatile and it faces challenges such as being dropped from several growth benchmarks while being added to value indices. Its ongoing Phase 2 trial for tibulizumab reflects active efforts in drug development amidst these transitions. Click here to discover the nuances of Zura Bio with our detailed analytical financial health report. Examine Zura Bio's earnings growth report to understand how analysts expect it to perform. Nextdoor Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Nextdoor Holdings, Inc. operates a neighborhood network that connects neighbors, businesses, and public agencies both in the United States and internationally, with a market cap of approximately $696.31 million. Operations: The company generates revenue of $248.31 million from its Internet Information Providers segment. Market Cap: $696.31M Nextdoor Holdings, Inc., with a market cap of US$696.31 million, trades significantly below its estimated fair value and remains debt-free. Despite being unprofitable with a negative return on equity and no forecasted profitability in the next three years, the company maintains sufficient cash runway for over three years without significant shareholder dilution recently. Recent developments include a major redesign of its platform to enhance user engagement through features like Alerts, News, and Faves. Additionally, Nextdoor has expanded advertising into Canada and completed a substantial share buyback program aimed at enhancing shareholder value. Unlock comprehensive insights into our analysis of Nextdoor Holdings stock in this financial health report. Understand Nextdoor Holdings' earnings outlook by examining our growth report. Elite Pharmaceuticals Simply Wall St Financial Health Rating: ★★★★★★ Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals, with a market cap of approximately $567.50 million. Operations: The company's revenue is primarily derived from its Abbreviated New Drug Applications (ANDA) segment, which generated $84.04 million. Market Cap: $567.5M Elite Pharmaceuticals, Inc., with a market cap of US$567.50 million, has shown revenue growth to US$84.04 million for the year ended March 31, 2025, despite reporting a net loss of US$4.31 million compared to the previous year's net income. The company maintains financial stability with short-term assets exceeding both short and long-term liabilities and has reduced its debt-to-equity ratio significantly over five years. Although unprofitable, Elite's operating cash flow covers its debt well and it hasn't seen meaningful shareholder dilution recently. However, significant insider selling in recent months could be a concern for potential investors. Dive into the specifics of Elite Pharmaceuticals here with our thorough balance sheet health report. Review our historical performance report to gain insights into Elite Pharmaceuticals' track record. Where To Now? Explore the 417 names from our US Penny Stocks screener here. Searching for a Fresh Perspective? AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ZURA KIND and ELTP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Protest against permanent closure of birthing unit
Residents from Lichfield took part in a walking protest to oppose the permanent closure of a maternity unit in Staffordshire. Campaigners said that "mothers need a real choice" and closing the birthing unit at Samuel Johnson Community Hospital for good would take away options for local families. Families took part in a pram push on Saturday after a public consultation was launched by the NHS Staffordshire and Stoke-on-Trent Integrated Care Board (ICB) last month. The freestanding midwife-led birthing units (FMBUs) at Samuel Johnson and County Hospital in Stafford were temporarily stopped due to the pandemic - the body is gathering views on whether they should reopen. Pregnant mothers have still been able to attend the hospitals for antenatal and postnatal appointments but have been unable to give birth at the units. While many have been waiting for the midwife-led services to resume, the ICB said the viability of the units was being questioned. Local residents, families who had used the maternity units in the past and pregnant mothers all gathered in the pouring rain in protest as they walked from Lichfield guildhall to Samuel Johnson. Hannah Weaver, who gave birth at the Lichfield unit before the pandemic, told the BBC her experience there was "empowering". She said: "I had an extremely positive and extremely empowering experience [at Samuel Johnson]. "I think it's important women have a choice about where they want to give birth, and that choice is being taken away from the residents of Lichfield. "The pram push is to show people we are against the proposal for closure and that we really make sure we keep safe births in Lichfield where there's choice. "That's the main thing - maternity choice." If services at the facility do not resume, the closest birthing unit for expectant mothers in Lichfield is at Queen's Hospital, in Burton. Speaking on the original decision to close the services, the ICB said it was made to ensure there was enough staff for the maternity departments at Royal Stoke University Hospital and Queen's Hospital in Burton-upon-Trent. Heather Johnstone, chief nursing and therapies officer, told the BBC if services were to resume, the midwives staffing the units would be taken away from the county's busiest hospitals. She said: "The units have been shut for five years, so the most recent data we have is from 2020. "There were around 18 births a month, so 220 births a year. It requires a lot of midwifery staffing to safely staff that unit. "It's taking those midwives away from facilities where they could be providing care to a broader range of people." The public consultation will run until 3 August and people have been urged to share their views on the ICB's website. Follow BBC Stoke & Staffordshire on BBC Sounds, Facebook, X and Instagram. More on this story Birthing unit closures could be made permanent Related internet links Staffordshire and Stoke-on-Trent ICB Samuel Johnson Community Hospital
Yahoo
an hour ago
- Yahoo
NHS managers who silence whistleblowers to be banned from senior health roles
NHS managers who silence whistleblowers will be banned from taking up other senior health service roles, the Government has announced. The Department of Health and Social Care (DHSC) said the proposals will ensure those who commit serious misconduct are no longer able to work in senior NHS management positions. Legislation is set to be put forward to Parliament next year to introduce professional standards and regulation of NHS managers. Tens of thousands of clinical and non-clinical managers work in the NHS but there is currently no regulatory framework specifically for managers, as there is for doctors and nurses. Health Secretary Wes Streeting said the reforms will 'slam the door in the face of unsuitable managers'. Mr Streeting added: 'I'm determined to create a culture of honesty and openness in the NHS where whistleblowers are protected, and that demands tough enforcement. 'If you silence whistleblowers, you will never work in the NHS again. 'We've got to create the conditions where staff are free to come forward and sound the alarm when things go wrong. Protecting the reputation of the NHS should never be put before protecting patient safety. 'Most NHS leaders are doing a fantastic job, but we need to stop the revolving door that allows managers sacked for misconduct or incompetence to be quietly moved to another well-paid role in another part of the NHS.' DHSC said a public consultation launched in November last year received more than 4,900 contributions on ways in which managers and leaders could be regulated. The statutory barring system will be for board-level directors and their direct reports within NHS bodies. Further legislation will set out new statutory powers for the Health and Care Professions Council to disbar NHS leaders in senior roles who have committed serious misconduct. Separate NHS England professional standards for managers will establish a 'consistent, national set of expectations about NHS management and leadership competency and conduct', DHSC said. Tom Kark KC, author of the Kark Review into the effectiveness of the fit and proper person test within the NHS, said: 'I am pleased that the recommendation made in my report into the application of the NHS fit and proper person test to create a power to disqualify board directors found guilty of serious misconduct is being implemented. 'Along with the ongoing implementation of my other recommendations for improving board competence, this is a positive move to strengthen management in the NHS by weeding out poor leadership. 'This is good news for whistleblowers and those looking for accountability in senior management which has long been lacking.' Rachel Power, chief executive of the Patients Association, said patients expect NHS managers 'to be held to the same high standards as clinical staff, and that should include consistent regulation'. Ms Power added: 'A clear, fair process to prevent those who commit serious misconduct from returning to senior roles will be an important step forward, and it's vital that patient involvement continues to shape proposals as further regulation is considered.' Sam Allen, NHS national director for leadership and management, said: 'Managers will welcome this new regulatory framework, as part of the broader package of actions set out in the plan to attract, develop, and retain the best possible leaders for the NHS of today and tomorrow.'
